The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens
Open accessAbstract
Background: With the introduction of integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy, persons living with HIV have a potent new treatment option. Recently, providers at our large treatment clinic noted weight gain in several patients who switched from efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) to dolutegravir/abacavir/lamivudine (DTG/ABC/3TC). In this study, we evaluated weight change in patients with sustained virologic suppression who switched from EFV/TDF/FTC to an INSTI-containing regimen. Methods: We performed a retrospective observational cohort study among adults on EFV/TDF/FTC for at least 2 years who had virologic suppression. We assessed weight change over 18 months in patients who switched from EFV/TDF/FTC to an INSTI-containing regimen or a protease inhibitor (PI)-containing regimen versus those on EFV/TDF/FTC over the same period. In a subgroup analysis, we compared patients switched to DTG/ABC/3TC versus raltegravir- or elvitegravir-containing regimens. Results: A total of 495 patients were included: 136 who switched from EFV/TDF/FTC to an INSTI-containing regimen and 34 switched to a PI-containing regimen. Patients switched to an INSTI-containing regimen gained an average of 2.9 kg at 18 months compared with 0.9 kg among those continued on EFV/TDF/FTC (P = 0.003), whereas those switched to a PI regimen gained 0.7 kg (P = 0.81). Among INSTI regimens, those switched to DTG/ABC/3TC gained the most weight at 18 months (5.3 kg, P = 0.001 compared with EFV/TDF/FTC). Conclusion: Adults living with HIV with viral suppression gained significantly more weight after switching from daily, fixed-dose EFV/TDF/FTC to an INSTI-based regimen compared with those remaining on EFV/TDF/FTC. This weight gain was greatest among patients switching to DTG/ABC/3TC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Raffi, F., Rachlis, A., Stellbrink, H.-J., Hardy, W. D., Torti, C., Orkin, C., Bloch, M., Podzamczer, D., Pokrovsky, V., Pulido, F., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61853-4 · Cited by 548
Cahn, P., Pozniak, A. L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J. F., Richmond, G., Buendia, C. B., Fourie, J., Ramgopal, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61221-0 · Cited by 516
Clotet, B., Feinberg, J., van Lunzen, J., Khuong-Josses, M.-A., Antinori, A., Dumitru, I., Pokrovskiy, V., Fehr, J., Ortiz, R., Saag, M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60084-2 · Cited by 507
Energy Expenditure and Wasting in Human Immunodeficiency Virus Infection
Macallan, D. C., Noble, C., Baldwin, C., Jebb, S. A., Prentice, A. M., Coward, W. A., Sawyer, M. B., McManus, T. J., & Griffin, G. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507133330202 · Cited by 393
Koethe, J. R., Jenkins, C. A., Lau, B., Shepherd, B. E., Justice, A. C., Tate, J. P., Buchacz, K., Napravnik, S., Mayor, A. M., Horberg, M. A., et al. (2016) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0147 · Cited by 337
Self-citationHIV infection and the risk of diabetes mellitus
Butt, A. A., McGinnis, K., Rodriguez-Barradas, M. C., Crystal, S., Simberkoff, M., Goetz, M. B., Leaf, D., & Justice, A. C. (2009) · AIDS · doi:10.1097/qad.0b013e32832bd7af · Cited by 321
Grunfeld, C., Pang, M., Shimizu, L., Shigenaga, J., Jensen, P., & Feingold, K. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/55.2.455 · Cited by 279
Increasing Rates of Obesity among HIV-Infected Persons during the HIV Epidemic
Crum-Cianflone, N., Roediger, M. P., Eberly, L., Headd, M., Marconi, V., Ganesan, A., Weintrob, A., Barthel, R. V., Fraser, S., Agan, B. K., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010106 · Cited by 247
Capeau, J., Bouteloup, V., Katlama, C., Bastard, J.-P., Guiyedi, V., Salmon-Ceron, D., Protopopescu, C., Leport, C., Raffi, F., & Chêne, G. (2012) · AIDS · doi:10.1097/qad.0b013e32834e8776 · Cited by 235
Cited by
Dolutegravir plus two different prodrugs of tenofovir to treat HIV
Venter, W. D. F., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., Serenata, C., Akpomiemie, G., Qavi, A., Chandiwana, N., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902824 · Cited by 723
Bourgi, K., Jenkins, C. A., Rebeiro, P. F., Shepherd, B. E., Palella, F., Moore, R. D., Althoff, K. N., Gill, J., Rabkin, C. S., Gange, S. J., et al. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25484 · Cited by 246
Self-citationObesity and weight gain in persons with HIV
Bailin, S. S., Gabriel, C. L., Wanjalla, C. N., & Koethe, J. R. (2020) · Current HIV/AIDS Reports · doi:10.1007/s11904-020-00483-5 · Cited by 213
Self-citationMcCann, K., Shah, S., Hindley, L., Hill, A., Qavi, A., Simmons, B., Serenata, C., Sokhela, S., & Venter, W. D. F. (2021) · AIDS · doi:10.1097/qad.0000000000002930 · Cited by 72
Kuo, P.-H., Sun, H.-Y., Chuang, Y.-C., Wu, P.-Y., Liu, W.-C., & Hung, C.-C. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.12.029 · Cited by 61
Metadata
- Authors
- Norwood, J., Turner, M., Bofill, C., Rebeiro, P., Shepherd, B., Bebawy, S., Hulgan, T., Raffanti, S., Haas, D. W., Sterling, T. R., & Koethe, J. R.
- Venue
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2017-12-15
- Volume
- 76
- Issue
- 5
- Pages
- 527-531
- ISSN
- 1525-4135 (ISSN-L)
- OpenAlex
- W2746406130
- Cited by
- 284
- References
- 31
- FWCI
- 20.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens. https://app.cochat.ai/papers/10.1097/qai.0000000000001525
- The paper
- Norwood, J., Turner, M., Bofill, C., Rebeiro, P., Shepherd, B., Bebawy, S., Hulgan, T., Raffanti, S., Haas, D. W., Sterling, T. R., & Koethe, J. R. (2017). Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based Regimens. JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/qai.0000000000001525
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.